LB-102 for the Treatment of Acutely Exacerbated Schizophrenia: Insights From the Principal Investigator
John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society.